Sensilia Laboratory is a French, family-owned and independent laboratory based in Gironde, France. Since 2019, we have been researching and manufacturing healthy, innovative wellness products.
Thinking about CBD for an arthritic dog? We break down what the science says about real effects, limits, safety, and legal status.
Published in
Natural IngredientsLong overlooked, cannabidiol (CBD), this compound extracted from Cannabis sativa L., is now being studied for its potential effects on pain and inflammation, two mechanisms at the heart of osteoarthritis. But its use in dogs remains surrounded by questions: how does it really work? What do clinical studies show? Is it well tolerated? And above all, is it authorized in France?
This article offers a clear, evidence-based overview of the current state of knowledge, drawing exclusively on the available veterinary scientific literature.
Hemp (Cannabis sativa L.) is one of the oldest plants cultivated by humans, used for millennia for its fibers, seeds… and sometimes for its medicinal properties. But it was only in the 20th century that researchers began to understand what was really hidden in this plant.
In 1940, American chemist Roger Adams succeeded in isolating for the first time a then little-known molecule: cannabidiol, or CBD. A discovery that went largely unnoticed, as scientific attention was focused more on another cannabis compound: THC, psychoactive, which would become famous for its psychotropic effects.
It was only with the discovery of the endocannabinoid system in the 1990s, a network of receptors involved in pain, inflammation, mood, and immunity, that researchers finally understood why these plant molecules can have effects on the body… including in animals.
This breakthrough changes everything: instead of being seen as a simple component among others, CBD becomes the subject of a growing number of studies, particularly for .
Today, the CBD used in pet dietary supplements comes mainly from industrial hemp, a cannabis variety naturally rich in CBD but containing very little THC (often less than 0.2%). Manufacturers then extract the various cannabinoids present in the plant to obtain formulas of varying concentration according to needs.
Once extracted from the plant, CBD can be presented in several forms, which are neither equal in terms of composition nor potential effects:
These different forms influence not only the perceived effect, but also bioavailability, tolerance, taste, and overall product quality.
CBD for dogs comes in several forms, but not all offer the same stability or dosing precision.
In practice: for joint support, oil remains the most serious form and the best studied.
CBD does not act directly on cartilage, but may modulate several pathways involved in the key mechanisms of joint disorders such as inflammation and pain.
Dogs' bodies (like humans') have an endocannabinoid system: a network of receptors (CB1, CB2), enzymes, and molecules produced naturally by the body. This system regulates pain, inflammation, immune response modulation, and mobility.
CB2 receptors are present in joint tissues, the synovial membrane, and certain immune cells involved in osteoarthritis. This explains why CBD can indirectly influence pain perception and the inflammatory response.
Several in vitro and preclinical studies show that CBD may:
These effects do not "repair" the joint but may limit chronic inflammation, which is at the heart of osteoarthritis-related pain.
CBD is not a classic analgesic. It acts rather on:
This effect may explain why some arthritic dogs seem less sensitive or more mobile in clinical studies.
Research on CBD in veterinary medicine is progressing rapidly. Studies are still limited, but they already reveal two well-documented areas of interest:
To date, only two studies have tested CBD in dogs via the transdermal route. They involve very few animals and are neither randomized nor controlled, which does not allow efficacy to be assessed under proper scientific conditions. These data therefore remain exploratory, and only the oral route currently has clinically usable results.
Current veterinary studies therefore focus on administering CBD to dogs by the oral route.
Study by Gamble et al. (2018)
22 arthritic dogs were followed in a crossover protocol where each received CBD and then a placebo successively. Treatment consisted of 2 mg/kg of CBD twice daily, as oral oil, for four weeks.
Results showed a marked decrease in pain according to the CBPI questionnaire, as well as an improvement in mobility measured by the Hudson score. Many owners reported that their dog moved more easily, seemed less stiff, and was more active day to day.
Treatment was overall well tolerated, with only a slight increase in ALP on blood tests, a liver enzyme that can rise when the liver metabolizes more of a product, with no sign of associated disease in this study.
This study became the reference because it was the first to demonstrate an observable clinical effect of CBD in canine osteoarthritis.
Study by Verrico et al. (2020)
In this double-blind study, researchers compared standard CBD to liposomal CBD, two very different formulations in terms of absorption. Arthritic dogs were divided into three groups: liposomal CBD (20 mg/day), standard CBD (50 mg/day), placebo.
Both forms of CBD allowed a reduction in pain and better mobility, but an essential point emerges: the liposomal formulation, better absorbed, achieved comparable results with a much lower dose.
This study illustrates how much bioavailability determines real efficacy of a CBD supplement.
Study by Patikorn et al. (2023)
To assess overall efficacy of CBD in canine osteoarthritis, researchers pooled data from five studies, representing 117 dogs.
General trends confirm previous work: several trials show a decrease in pain and better comfort in treated dogs.
However, the authors note that scientific certainty remains low. The sample sizes are small, the study durations short, and the methods highly heterogeneous. This meta-analysis serves as a reminder that, while the results are encouraging, we do not yet have the necessary perspective to consider CBD as an established treatment.
Study by Tasma et al. (2024)
This recent, more rigorous study included 42 dogs with mobility disorders, including many cases of osteoarthritis. Each dog received 5 mg/kg of CBD twice daily in a 45-day crossover protocol, sometimes alone, sometimes combined with non-steroidal anti-inflammatory drugs (NSAIDs).
Owners often perceived an improvement in comfort and mobility during CBD phases. However, more objective instrumental locomotion measures did not always confirm these improvements.
Furthermore, the CBD + NSAID combination led to a more marked elevation of certain liver enzymes, without clinical symptoms.
CBD may help some dogs, but results aren't consistent — and it should be used carefully alongside other treatments.
Pharmacokinetic studies (Samara et al., Polidoro et al., Limsuwan et al., Di Salvo et al.) examine how CBD behaves once in the dog's body: its absorption, bioavailability, and evolution over time from administration to elimination.
These studies show that CBD is rapidly absorbed in dogs, with a peak in the blood 1 to 2 hours after intake. This is generally the time when we begin to observe the first effects.
Its oral bioavailability is low and variable (between 13% and 19%), which explains why liposomal forms may seem more effective at reduced doses.
Because its half-life is short, most trials use twice-daily administration to maintain a stable effect. Half-life in pharmacokinetics corresponds to the time needed for a drug's concentration in the blood to decrease by half. It is the rate at which the body eliminates a substance.
Available clinical trials show that CBD is generally well tolerated in dogs at the doses and durations tested: 2 to 5 mg/kg twice daily in osteoarthritis studies (Gamble et al., Verrico et al., Talsma et al.), and up to 4 mg/kg per day for 6 months in healthy adult dogs with no major adverse effects. Even in the longest protocols, blood parameters remained within normal ranges, except for an isolated ALP elevation, reversible after stopping the product. No clinical signs of liver toxicity were observed.
To date, available data report no cases of severe overdose at the doses tested in veterinary medicine. The effects reported with excessive intake are rather benign: marked drowsiness, digestive upset, or transient ataxia, linked to excessive sedation.
Long-term studies also confirm that repeated administration may lead to a slight accumulation of CBD in the blood, but with no clinical consequence within the dosage limits used.
In practice, risks increase mainly when CBD is:
In these situations, extra caution and veterinary monitoring are recommended. In other cases, studies suggest that CBD use, even prolonged, remains safe as long as doses match those validated scientifically.
CBD does not act on cartilage or the progression of osteoarthritis. Its interest lies elsewhere: it may attenuate inflammation and modulate pain perception, which is sometimes enough to make movements a little more supple and days more comfortable. But it does not correct the cause of the problem.
Studies nonetheless show very variable responses from one dog to another. Some people become more mobile, while others hardly react at all. These differences seem linked to individual metabolism but also to the quality of the extract. The most convincing studies mainly concern broad-spectrum or full-spectrum oils, or liposomal formulas, which are better absorbed and more consistent than sweets or poorly standardized products.
If the veterinarian chooses to use it, dosage must remain adapted to the dog's weight and physical condition. Particular vigilance is needed in those already on treatment, especially anti-inflammatories. CBD remains not recommended in case of liver fragility.
Finally, an essential point: the legal framework. In France, only hemp seed oil is authorized in animal feed. Orally administered CBD is considered an unauthorized additive, and therefore cannot be sold legally for dogs to ingest.
Only products intended for topical application, without systemic absorption, are currently tolerated pending possible European developments, but these products have demonstrated no efficacy in any veterinary study.
CBD generates real interest for supporting arthritic dogs, and the scientific literature is beginning to shed light on its effects. Available studies show encouraging results on pain and mobility, but also great individual response variability. CBD does not repair the joint: its role remains that of comfort support, and not a long-term treatment.
Its efficacy depends heavily on extract quality, bioavailability, dosage, and the dog's health status. At studied doses, CBD appears generally well tolerated, but requires particular attention with concomitant treatments or liver fragility.
Finally, and crucially, in France, orally administered CBD for animals is not authorized. Pending a potential European regulatory framework, it remains essential to consult a veterinarian for any decisions and to prioritize proven solutions to support mobility (weight management, appropriate activity, Omega-3, physiotherapy).
This article was written by the R&D team at Laboratoire Sensilia, experts in animal nutrition.